Expression of miR-210 in relation to other measures of hypoxia and prediction of benefit from hypoxia modification in patients with bladder cancer

The addition of hypoxia modifiers carbogen and nicotinamide (CON) to radiotherapy (RT) improved overall survival (OS) in bladder cancer patients in the BCON phase III clinical trial. We investigate whether expression of hsa-miR-210 in BCON patient samples reflects hypoxia and predicts benefit from h...

ver descrição completa

Detalhes bibliográficos
Main Authors: Irlam-Jones, J, Eustace, A, Denley, H, Choudhury, A, Harris, A, Hoskin, P, West, C
Formato: Journal article
Idioma:English
Publicado em: Cancer Research UK 2016